Chimeric Allografts Induced by Short‐Term Treatment With Stem Cell–Mobilizing Agents Result in Long‐Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats. Issue 7 (26th February 2016)

• Record Type: Journal Article
• Authors: Hu, X.; Okabayashi, T.; Cameron, A. M.; Wang, Y.; Hisada, M.; Li, J.; Raccusen, L. C.; Zheng, Q.; Montgomery, R. A.; Williams, G. M.; Sun, Z.
• Is Part Of: American journal of transplantation. Volume 16:Issue 7(2016:Jul.)
• Page Start: 2055
• Page End: 2065
• Publication Date: 2016-02-26
• Subjects: translational research/science -- basic (laboratory) research/science -- kidney transplantation/nephrology -- regenerative medicine -- pathology/histopathology -- tolerance -- organ acceptance -- rejection: acute -- stem cells -- tissue injury and repair; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.13706
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : Transplant tolerance allowing the elimination of lifelong immunosuppression has been the goal of research for 60 years. The induction of mixed chimerism has shown promise and has been extended successfully to large animals and to the clinic; however, it remains cumbersome and requires heavy early immunosuppression. In this study, we reported that four injections of AMD3100, a CXCR4 antagonist, plus eight injections of low‐dose FK506 (0.05 mg/kg per day) in the first week after kidney transplantation extended survival, but death from renal failure occurred at 30–90 days. Repeating the same course of AMD3100 and FK506 at 1, 2 and 3 mo after transplant resulted in 92% allograft acceptance (n = 12) at 7 mo, normal kidney function and histology with no further treatment. Transplant acceptance was associated with the influx of host stem cells, resulting in a hybrid kidney and a modulated host immune response. Confirmation of these results could initiate a paradigm shift in posttransplant therapy. Abstract : In an acute rejection rat model, short‐term treatment with AMD3100 plus low‐dose FK506 and repeat dosing result in chimeric kidney allografts and long‐term transplant survival. See the companion article onpage 2066 .